| Old Articles: <Older 8601-8610 Newer> |
|---|
 |
Chemistry World
June 14, 2013
Sarah Houlton |
GSK fires Chinese R&D head in data investigation GSK's research head in China has been sacked after claims of misrepresented data in a research paper. The company has asked the journal, Nature Medicine, to retract the paper.   |
Chemistry World
June 14, 2013
Phillip Broadwith |
Pfizer and Takeda win $2.15bn in patent payout Pfizer and Takeda will share a $2.15 billion settlement after suing generic drugmakers Teva and Sun Pharmaceuticals for patent infringement. |
Chemistry World
June 14, 2013
Phillip Broadwith |
Companies urged to publish hidden clinical trial data If companies won't publish invisible and abandoned trial data, researchers should take matters into their own hands, scientists at Johns Hopkins University, US, propose. |
Chemistry World
June 12, 2013
Maria Burke |
'Scientific censorship' hamstringing psychoactive drug research Legal controls on psychoactive drugs have hindered neuroscience research and the discovery of new treatments for brain disorders in 'one of the most scandalous examples of scientific censorship in modern times', claim researchers. |
Chemistry World
June 10, 2013
Phillip Broadwith |
Sandoz manufacturing woes continue Sandoz, the generic drugs arm of Swiss firm Novartis, has had an official warning from the US Food and Drug Administration over failings at one of its manufacturing plants. |
Chemistry World
June 10, 2013
Phillip Broadwith |
AstraZeneca stocks pipeline with acquisitions AZ is also buying Omthera Pharmaceuticals for an up-front payment of $323 million, with a potential $120 million in milestone payments on offer. |
Chemistry World
June 7, 2013
Phillip Broadwith |
Job cuts at three US pharma companies Endo will shed 15% of its global workforce by mid 2014; Impax is cutting 110 manufacturing and sales positions (around 12% of its workforce); and Zogenix is laying off 55 of its 148 staff (37%). |
Chemistry World
June 6, 2013
Phillip Broadwith |
Big data to sniff out drug marketing fraud The US Food and Drug Administration is offering a contract for a company to collect and analyze data on pharma companies' promotional activities. The aim is to use this big data approach to spot off-label marketing and other forms of marketing fraud. |
Chemistry World
June 4, 2013
Maria Burke |
'Legal high' production gathers pace New designer drugs are popping up in Europe at an unprecedented rate, sometimes on the illicit drug market and sometimes as 'legal' alternatives to controlled drugs, according to the latest report by the EU drugs agency. |
Chemistry World
May 31, 2013
Phillip Broadwith |
Two new 'personalized' cancer drugs approved Two new drugs for the most deadly kind of skin cancer have been approved by the US Food and Drug Administration. The drugs are only effective in patients whose tumors express specific genetic mutations, which can be identified using a device approved alongside the drugs. |
| <Older 8601-8610 Newer> Return to current articles. |
